Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 12/2017

01-12-2017 | Lipid and Metabolic Effects of Gastrointestinal Surgery (R. Cohen, Section Editor)

Is Mini-Gastric Bypass a Rational Approach for Type-2 Diabetes?

Authors: Reem Abou Ghazaleh, Matthieu Bruzzi, Karen Bertrand, Leila M’harzi, Franck Zinzindohoue, Richard Douard, Anne Berger, Sébastien Czernichow, Claire Carette, Jean-Marc Chevallier

Published in: Current Atherosclerosis Reports | Issue 12/2017

Login to get access

Abstract

Purpose of Review

Morbid obesity and type-2 diabetes mellitus (T2DM) are both major public health problems. Bariatric surgery is a proven and effective treatment for these conditions; laparoscopic Roux-en-Y gastric bypass (RYGB) is currently the gold-standard treatment. One-anastomosis gastric bypass (OAGB) is described as a simpler, safer, and non-inferior alternative to RYGB to treat morbid obesity. Concerning T2DM, experts of the OAGB procedure report promising metabolic results with good long-term remission of T2DM; however, heterogeneity within the literature prompted us to analyze this issue.

Recent Findings

OAGB has gained popularity given its safety and long-term efficacy. Concerning the effect of OAGB for the treatment of T2DM, most reports involve non-controlled single-arm studies with heterogeneous methodologies and a few randomized controlled trials. However, this available literature supports the efficacy of OAGB for remission of T2DM in obese and non-obese patients. Two years after OAGB, the T2DM remission and improvement rate increased from 67 to 100%. The results were improved and stable in the long term. The 5-year T2DM remission rate increased from 82 to 84.4%. OAGB is non-inferior compared with RYGB and even superior to other accepted bariatric procedures, such as sleeve gastrectomy and adjustable gastric banding.

Summary

OAGB is an efficient, safe, simple, and reversible procedure to treat T2DM. The literature reveals interesting results for T2DM remission in non-obese patients. High-level comparative studies are required to support these data.
Literature
1.
•• Nguyen NT, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. Nat Rev Gastroenterol Hepatol. 2017;14(3):160–9. Important review of bariatric surgery. CrossRefPubMed
2.
• Dixon JB, Zimmet P, Alberti KG, Rubino F. Bariatric surgery: an IDF statement for obese Type 2 diabetes. Diabet Med. 2011;28:628–42. Statement for the surgical treatment of type-2 diabetes. CrossRefPubMedPubMedCentral
3.
Alberti KGMM, Zimmet P, Shaw J. International diabetes federation: a consensus on type 2 diabetes prevention. Diab Med. 2007;24:451–63.CrossRef
4.
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.CrossRefPubMed
5.
Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMed
6.
7.
Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMed
8.
•• Sjöström L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273:219–34. Prospective controlled study that proved the superiority of surgery. CrossRefPubMed
9.
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Brethauer SA, Navaneethan SD, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370:2002–13.CrossRefPubMedPubMedCentral
10.
•• Rubino F. Medical research: time to think differently about diabetes. Nature. 2016;533:459–61. Future of the research in diabetes treatment. CrossRefPubMed
11.
• Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11. Important research. CrossRefPubMedPubMedCentral
12.
•• Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244:741–9. Mechanism of diabetes control after gastric bypass. CrossRefPubMedPubMedCentral
13.
Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42.CrossRefPubMedPubMedCentral
14.
15.
16.
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73.CrossRefPubMed
17.
Rutledge R. The mini-gastric bypass: experience with the first 1,274 cases. Obes Surg. 2001;11:276–80.CrossRefPubMed
18.
Rutledge R, Walsh TR. Continued excellent results with the mini-gastric bypass: six-year study in 2,410 patients. Obes Surg. 2005;15:1304–8.CrossRefPubMed
19.
Lee WJ, Lin YH. Single-anastomosis gastric bypass (SAGB): appraisal of clinical evidence. Obes Surg. 2014;24:1749–56.CrossRefPubMed
20.
Lee WJ, Yu PJ, Wang W, Chen TC, Wei PL, Huang MT. Laparoscopic Roux-en-Y versus mini-gastric bypass for the treatment of morbid obesity: a prospective randomized controlled clinical trial. Ann Surg. 2005;242:20–8.CrossRefPubMedPubMedCentral
21.
Lee WJ, Ser KH, Lee YC, Tsou JJ, Chen SC, Chen JC. Laparoscopic Roux-en-Y vs. mini-gastric bypass for the treatment of morbid obesity: a 10-year experience. Obes Surg. 2012;22:1827–34.CrossRefPubMed
22.
Chevallier JM, Chakhtoura G, Zinzindohoué F. Laparoscopic mini-gastric bypass. J Chir. 2009;146:60–4.CrossRef
23.
•• Chevallier JM, Arman G, Guenzi M, Rau C, Bruzzi M, Beaupel N, et al. One thousand single anastomosis (Omega Loop) gastric bypasses to treat morbid obesity in a 7-year period: outcomes show few complications and good efficacy. Obes Surg. 2015;25:951–8. Results of 1000 OAGB of our team. CrossRefPubMed
24.
Bruzzi M, Rau C, Voron T, Guenzi M, Berger A, Chevallier JM. Single anastomosis or mini-gastric bypass: long-term results and quality of life after a 5-year follow-up. Surg Obes Relat Dis. 2015;11:321–6.CrossRefPubMed
25.
• Musella M, Susa A, Greco F, De Luca M, Manno E, Di Stefano C, et al. The laparoscopic mini-gastric bypass: the Italian experience: outcomes from 974 consecutive cases in a multicenter review. Surg Endosc. 2014;28:156–63. Results of 1000 OAGB of a reference team. CrossRefPubMed
26.
•• Musella M, Apers J, Rheinwalt K, Ribeiro R, Manno E, Greco F, et al. Efficacy of bariatric surgery in type 2 diabetes mellitus remission: the role of mini gastric bypass/one anastomosis gastric bypass and sleeve gastrectomy at 1 year of follow-up. A European survey. Obes Surg. 2016;26:933–40. Multicentric European results of OAGB in the treatment of diabetes. CrossRefPubMed
27.
Carbajo M, García-Caballero M, Toledano M, Osorio D, García-Lanza C, Carmona JA. One-anastomosis gastric bypass by laparoscopy: results of the first 209 patients. Obes Surg. 2005;15:398–404.CrossRefPubMed
28.
•• Zubiaga L, Abad R, Ruiz-Tovar J, Enriquez P, Vílchez JA, Calzada M, et al. The effects of one-anastomosis gastric bypass on glucose metabolism in Goto-Kakizaki rats. Obes Surg. 2016;26:2622–8. Research concerning the effects of OAGB on glycemic control in rats. CrossRefPubMed
29.
Bruzzi M, Duboc H, Gronnier C, Rainteau D, Couvelard A, Le Gall M, et al. Long-term evaluation of biliary reflux after experimental one-anastomosis gastric bypass in rats. Obes Surg. 2017;27:1119–22.CrossRefPubMed
30.
Deitel M. 2015Letter to the Editor: bariatric surgery worldwide reveals a rise in mini-gastric bypass. Obes Surg. 2013;25:2166–8.
31.
Georgiadou D, Sergentanis TN, Nixon A, Diamantis T, Tsigris C, Psaltopoulou T. Efficacy and safety of laparoscopic mini gastric bypass. A systematic review. Surg Obes Relat Dis. 2014;10:984–91.CrossRefPubMed
32.
Mahawar KK, Jennings N, Brown J, Gupta A, Balupuri S, Small PK. “Mini” gastric bypass: systematic review of a controversial procedure. Obes Surg. 2013;23:1890–8.CrossRefPubMed
33.
Mahawar KK, Carr WRJ, Balupuri S, Small PK. 2013Controversy surrounding “mini” gastric bypass. Obes Surg. 2014;24:324–33.CrossRefPubMed
34.
• Mahawar KK, Kumar P, Carr WR, Jennings N, Schroeder N, Balupuri S, et al. Current status of mini-gastric bypass. J Minim Access Surg. 2016;12:305–10. Review of the OAGB results. CrossRefPubMedPubMedCentral
35.
Victorzon M. Single-anastomosis gastric bypass: better, faster, and safer? Scand J Surg. 2015;104:48–53.CrossRefPubMed
36.
Chakhtoura G, Zinzindohoué F, Ghanem Y, Ruseykin I, Dutranoy JC, Chevallier JM. Primary results of laparoscopic mini-gastric bypass in a French obesity-surgery specialized university hospital. Obes Surg. 2008;18:1130–3.CrossRefPubMed
37.
Bruzzi M, Voron T, Zinzindohoue F, Berger A, Douard R, Chevallier JM. Revisional single-anastomosis gastric bypass for a failed restrictive procedure: 5-year results. Surg Obes Relat Dis. 2016;12:240–5.CrossRefPubMed
38.
•• Carbajo MA, Luque-de-Leon E, Jimenez JM, Ortiz-de-Solorzano J, Perez-Miranda M, Castro-Alija MJ. Laparoscopic one-anastomosis gastric bypass: technique, results, and long-term follow-up in 1200 patients. Obes. Surg. 2017;27:1153–67. Results of 1200 AOGB patients with a follow-up exceeding 10 years (for some patients). CrossRefPubMed
39.
Noun R, Riachi E, Zeidan S, Abboud B, Chalhoub V, Yazigi A. Mini-gastric bypass by mini-laparotomy: a cost-effective alternative in the laparoscopic era. Obes Surg. 2007;17:1482–6.CrossRefPubMed
40.
Noun R, Skaff J, Riachi E, Daher R, Antoun NA, Nasr M. One thousand consecutive mini-gastric bypass: short- and long-term outcome. Obes Surg. 2012;22:697–703.CrossRefPubMed
41.
Kular KS, Manchanda N, Rutledge R. A 6-year experience with 1,054 mini-gastric bypasses—first study from Indian subcontinent. Obes Surg. 2014;24:1430–5.CrossRefPubMed
42.
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Laparoscopic mini-gastric bypass: experience with tailored bypass limb according to body weight. Obes Surg. 2008;18:294–9.CrossRefPubMed
43.
Lee WJ, Wang W, Lee YC, Huang MT, Ser KH, Chen JC. Effect of laparoscopic mini-gastric bypass for type 2 diabetes mellitus: comparison of BMI>35 and <35 kg/m2. J Gastrointest Surg. 2008;12:945–52.CrossRefPubMed
44.
Wang W, Wei PL, Lee YC, Huang MT, Chiu CC, Lee WJ. Short-term results of laparoscopic mini-gastric bypass. Obes Surg. 2005;15:648–54.CrossRefPubMed
45.
Guenzi M, Arman G, Cordun C, Moszkowicz D, Voron T, Chevallier JM. Remission of type 2 diabetes after omega loop gastric bypass for morbid obesity. Surg Endosc. 2015;29:2669–74.CrossRefPubMed
46.
•• Quan Y, Huang A, Ye M, Xu M, Zhuang B, Zhang P, et al. Efficacy of laparoscopic mini gastric bypass for obesity and type 2 diabetes mellitus: a systematic review and meta-analysis. Gastroenterol Res Pract. 2015;2015:152852. Meta-analysis of OAGB and type-2 diabetes. CrossRefPubMedPubMedCentral
47.
48.
• Lee WJ, Chong K, Lin Y, Wei J, Chen S. Laparoscopic sleeve Gastrectomy versus single anastomosis (mini- ) gastric bypass for the treatment of type 2 diabetes mellitus : 5-year results of a randomized trial and study of incretin effect. Obes Surg. 2014;24:1552–62. A randomized trial comparing OAGB and sleeve. CrossRefPubMed
49.
Kular KS, Manchanda N, Rutledge R. Analysis of the five-year outcomes of sleeve gastrectomy and mini-gastric bypass: a report from the Indian sub-continent. Obes Surg. 2014;24:1724–8.CrossRefPubMed
50.
Celik A, Pouwels S, Karaca FC, Cagiltay E, Ugale S, Etikan I, et al. Time to glycemic control—an observational study of 3 different operations. Obes Surg. 2017;27:694–702.CrossRefPubMed
51.
Garcia-Caballero M, Valle M, Martinez-Moreno JM, Miralles F, Toval JA, Mata JM, et al. Resolution of diabetes mellitus and metabolic syndrome in normal weight 24-29 BMI patients with one anastomosis gastric bypass. Nutr Hosp. 2012;27:623–31.PubMed
52.
Kular KS, Manchanda N, Cheema GK. Seven years of mini-gastric bypass in type II diabetes patients with a body mass index <35 kg/m2. Obes Surg. 2016;26:1457–62.CrossRefPubMed
53.
Bruzzi M, Chevallier JM, Czernichow S. One-anastomosis gastric bypass: why biliary reflux remains controversial? Obes Surg. 2017;27:545–7.CrossRefPubMed
54.
DeMaria EJ, Sugerman HJ, Kellum JM, Meador JG, Wolfe LG. Results of 281 consecutive total laparoscopic Roux-en-Y gastric bypasses to treat morbid obesity. Ann Surg. 2002;235:640–5.CrossRefPubMedPubMedCentral
55.
Schauer PR, Ikramuddin S, Gourash W, Ramanathan R, Luketich J. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.CrossRefPubMedPubMedCentral
56.
Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases. Obes Surg. 1994;4:353–7.CrossRefPubMed
57.
Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg. 2000;10:233–9.CrossRefPubMed
58.
Rubino F, Kaplan LM, Schauer PR, Cummings DE. The diabetes surgery summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg. 2010;251:399–405.CrossRefPubMed
59.
• Cummings DE, Arterburn DE, Westbrook EO, Kuzma JN, Stewart SD, Chan CP, et al. Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial. Diabetologia. 2016;59:945–53. Randomized controlled trial. CrossRefPubMedPubMedCentral
Metadata
Title
Is Mini-Gastric Bypass a Rational Approach for Type-2 Diabetes?
Authors
Reem Abou Ghazaleh
Matthieu Bruzzi
Karen Bertrand
Leila M’harzi
Franck Zinzindohoue
Richard Douard
Anne Berger
Sébastien Czernichow
Claire Carette
Jean-Marc Chevallier
Publication date
01-12-2017
Publisher
Springer US
Published in
Current Atherosclerosis Reports / Issue 12/2017
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-017-0689-3

Other articles of this Issue 12/2017

Current Atherosclerosis Reports 12/2017 Go to the issue

Lipid and Metabolic Effects of Gastrointestinal Surgery (R. Cohen, Section Editor)

Cardiovascular Risk Factors After Single Anastomosis Duodeno-Ileal Bypass with Sleeve Gastrectomy (SADI-S): a New Effective Therapeutic Approach?

Cardiovascular Disease and Stroke (S. Prabhakaran, Section Editor)

Delayed Cerebral Ischemia after Subarachnoid Hemorrhage: Beyond Vasospasm and Towards a Multifactorial Pathophysiology

Cardiovascular Disease and Stroke (S. Prabhakaran, Section Editor)

Early Rehabilitation After Stroke: a Narrative Review

Cardiovascular Disease and Stroke (Shyam Prabhakaran, Section Editor)

Community Interventions to Increase Stroke Preparedness and Acute Stroke Treatment Rates

Nonstatin Drugs (E. deGoma, Section Editor)

Antiplatelet Therapy for Secondary Prevention of Vascular Disease Complications

Cardiovascular Disease and Stroke (Shyam Prabhakaran, Section Editor)

Improving Regional Stroke Systems of Care
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits